Related Experiment Videos
Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network
U A Wagner1, P F Oehr, J Reinsberg
1Department of Obstetrics and Gynecology, University of Bonn, Germany.
Abstract:
The positive effect of an immunotherapy using tumor-associated antigens or tumor cells of ovarian carcinomas has not yet been proven. Although many unique tumor-associated antigens have been described and a tumor rejection could be seen in occasional cases, the failure of the immune system to destroy tumor cells is not clearly understood. An alternative approach is to initiate the idiotypic network utilizing antibodies (Ab1 or 2) against a tumor-associated antigen, which induces the production of anti-idiotypic-antibodies (Ab2 beta), mimicking the "internal image" of the tumor-associated antigen. These antibodies are able to induce a specific antitumor immunity in two ways: (1) the Ab2 can present the critical epitope in a different way and so modulates the immune system, or (2) it can induce the production of an Ab3, which by itself binds to the tumor antigen. Our first results on 22 patients with advanced ovarian carcinomas show that the induction of an anti-idiotypic antibody (Ab2 beta) against OC 125 mimicking the TAA Class III CA 125 leads to a prolongation of the survival rate also for extended stages. We see a beneficial role of the induction of the idiotypic network against a tumor-associated antigen showing delayed clinical courses of the disease after vaccination of the patients with antibody fragments of the OC 125.
Insights
This study explores idiotypic network immunotherapy for ovarian cancer. Inducing anti-idiotypic antibodies (Ab2 beta) against tumor antigens shows promise in prolonging survival rates for advanced ovarian carcinoma patients.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- The efficacy of direct immunotherapy with tumor-associated antigens for ovarian cancer remains unproven.
- The precise mechanisms behind the immune system's failure to eliminate ovarian tumor cells are not fully understood.
- The idiotypic network offers an alternative immunotherapeutic strategy.
Purpose of the Study:
- To investigate the potential of idiotypic network induction for treating advanced ovarian carcinomas.
- To evaluate the impact of anti-idiotypic antibodies (Ab2 beta) mimicking tumor-associated antigens on patient survival.
- To explore the role of idiotypic network activation in modulating antitumor immunity.
Main Methods:
- Vaccination of 22 advanced ovarian carcinoma patients with antibody fragments of OC 125.
- Induction of anti-idiotypic antibodies (Ab2 beta) targeting the TAA Class III CA 125.
- Monitoring clinical courses and survival rates post-vaccination.
Main Results:
- The induction of Ab2 beta against OC 125 demonstrated a prolongation of survival rates in patients with advanced ovarian carcinomas.
- A beneficial role for idiotypic network induction was observed, leading to delayed disease progression.
- The treatment showed a positive impact on the clinical course of the disease.
Conclusions:
- Idiotypic network immunotherapy, specifically using Ab2 beta against tumor-associated antigens like CA 125, presents a viable approach for ovarian cancer.
- This strategy can induce specific antitumor immunity and improve survival outcomes in advanced stages.
- Further research into antibody fragments and idiotypic networks is warranted for ovarian cancer treatment.